Eculizumab clinical trials
Also written Soliris.
How each study uses eculizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eculizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Mar 2007 · SOLIRIS · BLA 125166 (FDA, Drugs@FDA)
- European Union
- 20 Jun 2007 · Soliris · EMEA/H/C/000791 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
81 studies that test it; most in 2009 (8)
| Year | Studies |
|---|---|
| 2004 | 4 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 40
Alexion Pharmaceuticals, Inc. (31) · Biocad (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Mayo Clinic (3) · Assistance Publique - Hôpitaux de Paris (3) · Tianjin Medical University General Hospital (2) · Samsung Bioepis Co., Ltd. (2) · Johns Hopkins University (2)
Often tested with
Tested in the same studies.
Ravulizumab (3) · HRS-5965 (1) · Satralizumab (1) · Inebilizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Eculizumab is the comparator. A study of two new drugs counts under both.
- 1Crovalimab · Hoffmann-La Roche · next primary completion Apr 2027
- 1VSA012 · Bisirna Therapeutics (Suzhou) Co., Ltd. · next primary completion Sep 2027
- 1FXS6837 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · next primary completion May 2028
- 1NTQ5082 · Nanjing Chia-tai Tianqing Pharmaceutical · next primary completion Nov 2026
- 1Lanoracopan · Wuhan Createrna Science and Technology Co., Ltd
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test eculizumab, phase 3 first.
- Dec 2026Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDPhase 3 · Alexion Pharmaceuticals, Inc.
- Jun 2027Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyPhase 4 · Chinese PLA General Hospital
Studies
Open first, then newest update. How each study uses eculizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 81
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Eculizumab (Soliris®)
- Safety and Efficacy of Eculizumab in High-risk TA-TMARecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07707687Written as Eculizumab
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyRecruitingPhase 4Chinese PLA General HospitalNCT07410039Written as Eculizumab+IVMP
- Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney TransplantationNot yet recruitingPhase 1/2Tao LinNCT06453135Written as Eculizumab
- Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic SyndromeRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT05726916Written as Soliris®
- Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUSCompletedPhase 4Nantes University HospitalNCT02574403Written as eculizumab
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum DisorderActive, not recruitingPhase 2Tianjin Medical University General HospitalNCT07184840Written as Complement protein C5 inhibitor
- Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT05886244Written as Eculizumab
- Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHUCompletedPhase 3University Hospital, ToulouseNCT02205541Written as Eculizumab
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT06764160Written as Eculizumab
- Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06724809Written as eculizumab
- Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT05876351Written as Eculizumab
- Complement C5 mAb in the Treatment of Anti-GBM DiseaseCompletedPhase 2Peking University First HospitalNCT06513338Written as Eculizumab
- Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney TransplantationWithdrawnPhase 1/2Assistance Publique - Hôpitaux de ParisNCT02113891Written as Eculizumab
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT06593938Written as Eculizumab Injection
- Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum DisorderWithdrawnPhase 2Tianjin Medical University General HospitalNCT06673394Written as Complement protein C5 inhibitor
- A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré SyndromeCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04752566Written as Eculizumab
- An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedPhase 3BiocadNCT06987864Written as eculizumab
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Eculizumab
- A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03759366Written as Eculizumab
See all 81 studies that test eculizumab →
Given beside what is tested · 9 — eculizumab is usual care or a partner of the new treatment
- Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisNot yet recruitingPhase 2NovelMed TherapeuticsNCT05646563Written as Soliris
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedPhase 2BioCryst PharmaceuticalsNCT05116774Written as Eculizumab
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentCompletedPhase 3Regeneron PharmaceuticalsNCT05133531Written as Eculizumab
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04434092Written as Eculizumab
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedPhase 2BioCryst PharmaceuticalsNCT04702568Written as Eculizumab
- ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03056040Written as Eculizumab
- ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT02946463Written as Eculizumab
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT03472885Written as Eculizumab
- Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Apellis Pharmaceuticals, Inc.NCT03500549Written as Soliris
As the comparator · 9 — what is tested is compared with eculizumab
- A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyNot yet recruitingPhase 3Bisirna Therapeutics (Suzhou) Co., Ltd.NCT07816237Written as Eculizumab (Soliris®)
- A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Not yet recruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07747090Written as Eculizumab infusion
- A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsNot yet recruitingPhase 3Nanjing Chia-tai Tianqing PharmaceuticalNCT07177859Written as Eculizumab Injection
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932744Written as Eculizumab Injection
- Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy ParticipantsRecruitingPhase 1Turgut Ardika PTY LTDNCT05863442Written as Soliris 300 MG in 30 ML Injection
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04432584Written as Eculizumab
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxCompletedPhase 3Hansa Biopharma ABNCT04935177Written as Eculizumab
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT06799546Written as Eculizumab Injection
- Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedPhase 3Novartis PharmaceuticalsNCT04558918Written as Eculizumab
Codes
What other systems call eculizumab · ClinicalTrials.gg INT004609
- MeSH (NLM) C481642eculizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A3ULP0F556ECULIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 591781Confirmed FDA, Wikidata
- Wikidata Q421617eculizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48386EculizumabOne source FDA
- DrugBank DB01257One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C481642 | eculizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A3ULP0F556 | ECULIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 591781 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421617 | eculizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48386 | Eculizumab | One source FDA |
| DrugBank | DB01257 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.